Bluebird Bio Inc. (BLUE) PT Raised to $80.00 at Leerink Swann
Bluebird Bio Inc. (NASDAQ:BLUE) had its price objective hoisted by equities researchers at Leerink Swann from $67.00 to $80.00 in a research report issued on Friday. The brokerage currently has an “outperform” rating on the stock. Leerink Swann’s price target would indicate a potential upside of 22.62% from the stock’s current price.
BLUE has been the topic of a number of other reports. Jefferies Group restated a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Friday, September 23rd. Zacks Investment Research lowered shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. SunTrust Banks Inc. restated a “buy” rating on shares of Bluebird Bio in a research report on Friday. Maxim Group set a $85.00 price target on shares of Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Finally, Cowen and Company restated an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $90.82.
Bluebird Bio (NASDAQ:BLUE) traded down 5.9497% during mid-day trading on Friday, reaching $61.3584. 889,442 shares of the company were exchanged. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70. The company’s market capitalization is $2.28 billion. The company has a 50 day moving average of $63.52 and a 200-day moving average of $50.81.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/bluebird-bio-inc-blue-pt-raised-to-80-00-at-leerink-swann.html
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The company earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same quarter last year, the business earned ($1.57) EPS. The firm’s revenue for the quarter was down 68.6% compared to the same quarter last year. On average, equities research analysts forecast that Bluebird Bio will post ($6.19) EPS for the current year.
In related news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now directly owns 4,656 shares of the company’s stock, valued at approximately $209,706.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 3.50% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Cupps Capital Management LLC acquired a new stake in shares of Bluebird Bio during the third quarter valued at $1,824,000. Gradient Investments LLC acquired a new stake in shares of Bluebird Bio during the third quarter valued at $333,000. First Mercantile Trust Co. acquired a new stake in shares of Bluebird Bio during the third quarter valued at $129,000. BNP Paribas Arbitrage SA increased its stake in shares of Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock valued at $209,000 after buying an additional 1,619 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Bluebird Bio by 43.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 145,569 shares of the company’s stock valued at $6,302,000 after buying an additional 44,048 shares during the last quarter.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.